Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rua Bioscience's Enterprise Value is NZ$13.84 Mil.
Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-3.17 Mil. Therefore, Rua Bioscience's EV-to-EBIT ratio for today is -4.36.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Rua Bioscience's Enterprise Value is NZ$13.84 Mil.
Rua Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.77 Mil. Therefore, Rua Bioscience's EV-to-EBITDA ratio for today is -5.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Rua Bioscience's Enterprise Value is NZ$13.84 Mil.
Rua Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$2.15 Mil. Therefore, Rua Bioscience's EV-to-Revenue ratio for today is 6.44.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Rua Bioscience's Enterprise Value is NZ$13.84 Mil.
Rua Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.30 Mil. Therefore, Rua Bioscience's EV-to-FCF ratio for today is -6.03.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Rua Bioscience (NZSE:RUA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-3.17 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.77 Mil.
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$2.15 Mil.
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.30 Mil.
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rua Bioscience Enterprise Value Related Terms
Rua Bioscience Enterprise Value Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:RUA vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rua Bioscience Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Rua Bioscience's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Rua Bioscience's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NZ$13.84 Mil mean?
Rua Bioscience (NZSE:RUA) has a Enterprise Value of NZ$13.84 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Rua Bioscience and its competitors.
Is Rua Bioscience's Enterprise Value too high?
Rua Bioscience's current Enterprise Value is NZ$13.84 Mil.
How does Rua Bioscience's Enterprise Value compare to ZTS and UTHR?
Rua Bioscience's Enterprise Value of NZ$13.84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Rua Bioscience and its competitors. Rua Bioscience's current Enterprise Value is NZ$13.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current Enterprise Value of NZ$13.84 Mil. The current Enterprise Value is NZ$13.84 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current Enterprise Value is NZ$13.84 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
